Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes (vol 42, 10.1200/JCO.23.01994, 2024)

被引：2
|
作者：
Rastogi, Priya
O'Shaughnessy, Joyce
Martin, Miguel
Boyle, Frances
Cortes, Javier
Rugo, Hope S.
Goetz, Matthew P.
Hamilton, Erika P.
Huang, Chiun-Sheng
Senkus, Elzbieta
Tryakin, Alexey
Cicin, Irfan
Testa, Laura
Neven, Patrick
Huober, Jens
Shao, Zhimin
Wei, Ran
Andre, Valerie
Munoz, Maria
San Antonio, Belen
Shahir, Ashwin
Harbeck, Nadia
Johnston, Stephen
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 17期
关键词：
D O I：
10.1200/JCO.24.00711
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2111 / 2111
页数：1
相关论文
共 50 条
  • [21] Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2
    Campone, Mario
    Im, Seock-Ah
    Iwata, Hiroji
    Clemons, Mark
    Ito, Yoshinori
    Awada, Ahmad
    Chia, Stephen
    Jagiello-Gruszfeld, Agnieszka
    Pistilli, Barbara
    Tseng, Ling-Ming
    Hurvitz, Sara
    Masuda, Norikazu
    Cortes, Javier
    De Laurentiis, Michele
    Arteaga, Carlos L.
    Jiang, Zefei
    Jonat, Walter
    Le Mouhaer, Sylvie
    Sankaran, Banu
    Bourdeau, Laurence
    El-Hashimy, Mona
    Sellami, Dalila
    Baselga, Jose
    EUROPEAN JOURNAL OF CANCER, 2018, 103 : 147 - 154
  • [22] Abemaciclib combined with endocrine therapy as adjuvant treatment for hormone-receptor-positive, HER2-, high-risk early breast cancer: 5-year Chinese population analysis of the phase III randomized monarchE study
    Zhang, Qingyuan
    Shen, Kunwei
    Song, Chuan-gui
    Ouyang, Quchang
    Liu, Zhenzhen
    Liu, Qiang
    Feng, Jifeng
    Chiu, Joanne W. Y.
    Tang, Jinhai
    Jiang, Zefei
    Tseng, Ling-Ming
    Wang, Xiaojia
    Yang, Liu
    Qian, Chenxi
    Shao, Zhimin
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16
  • [23] Association of Adjuvant Hormone Therapy Timing With Overall Survival Among Patients With Hormone Receptor-Positive Human Epidermal Growth Factor Receptor-2-Negative Early Breast Cancer Without Chemotherapy
    Fu, Fangmeng
    Yu, Liuwen
    Zeng, Bangwei
    Chen, Minyan
    Guo, Wenhui
    Chen, Lili
    Lin, Yuxiang
    Hou, Jialin
    Li, Jing
    Li, Yan
    Li, Shengmei
    Chen, Xiaobin
    Zhang, Wenzhe
    Jin, Xuan
    Cai, Weifeng
    Zhang, Kun
    Chen, Hanxi
    Qiu, Yibin
    Nie, Qian
    Wang, Chuan
    Jacobs, Lisa
    JAMA NETWORK OPEN, 2022, 5 (02) : E2145934
  • [24] Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials
    Regan, Meredith M.
    Francis, Prudence A.
    Pagani, Olivia
    Fleming, Gini F.
    Walley, Barbara A.
    Viale, Giuseppe
    Colleoni, Marco
    Lang, Istvan
    Gomez, Henry L.
    Tondini, Carlo
    Pinotti, Graziella
    Price, Karen N.
    Coates, Alan S.
    Goldhirsch, Aron
    Gelber, Richard D.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (19) : 2221 - +
  • [25] Invasive disease-free survival as a surrogate for overall survival in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer: a real-world analysis
    Graff, Stephanie
    Tolaney, Sara
    Hart, Lowell
    Razavi, Pedram
    Janni, Wolfgang
    Schwartzberg, Lee
    Danyliv, Andrii
    Payan, Juan Carlos Mora
    Ferrusi, Ilia
    Adhikary, Rishi Rajat
    O'Shaughnessy, Joyce
    CANCER RESEARCH, 2024, 84 (09)
  • [26] MONARCH E: A phase 3 study of standard adjuvant endocrine therapy with or without abemaciclib in patients with high risk, node positive, hormone-receptor positive, human epidermal growth factor receptor 2-negative early-stage breast cancer
    Rastogi, Priya
    Toi, Masakazu
    Martin, Miguel
    O'Shaughnessy, Joyce
    Headley, Desiree
    Wei, Jennifer
    Cox, Joanne
    Harbeck, Nadia
    Johnston, Stephen
    CANCER RESEARCH, 2020, 80 (04)
  • [27] Combination of palbociclib with adjuvant endocrine therapy for treatment of hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer: An experience at two cancer centers in Saudi Arabia
    Al-Foheidi, Meteb H.
    Albeshri, Asem Mohammed
    Moamenkahan, Safwan Noor
    Abdullah, Abdulmajid Mohammed
    Abualola, Muhannad Sadaqa
    Alharbi, Muath Hamed
    Refa, Ahmed A.
    Bayer, Ali M.
    Shaheen, Ahmed Y.
    Aga, Syed Sameer
    Khan, Muhammad Anwar
    Al-Mansour, Mubarak M.
    Ibrahim, Ezzeldin M.
    MOLECULAR AND CLINICAL ONCOLOGY, 2022, 17 (01)
  • [28] NATALEE: Phase III study of ribociclib (RIBO) plus endocrine therapy (ET) as adjuvant treatment in hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) early breast cancer (EBC).
    Slamon, Dennis J.
    Fasching, Peter A.
    Patel, Ravindranath
    Verma, Sunil
    Hurvitz, Sara A.
    Chia, Stephen K. L.
    Crown, John
    Martin, Miguel
    Barrios, Carlos H.
    Spera, Gonzalo
    Lopez, Celine
    Hor, Ines
    Pelov, Diana
    Hughes, Gareth
    Nawinne, Moditha
    Hortobagyi, Gabriel N.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [29] RIBOCICLIB AND ENDOCRINE THERAPY (ET) IN HORMONE RECEPTOR-POSITIVE (HR plus ), HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HER-2) BREAST CANCER: THE MONALEESA CLINICAL TRIALS PROGRAM
    Campone, Mario
    Tripathy, Debu
    Chia, Stephen
    Diaz-Padilla, Ivan
    Lorenc, Karen R.
    Miller, Michelle
    Germa, Caroline
    Conte, Pierfranco
    BREAST, 2017, 36 : S50 - S50
  • [30] Assessment of nuclear grade-based recurrence risk classification in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative, node-positive high-risk early breast cancer
    Takeshi Murata
    Masayuki Yoshida
    Sho Shiino
    Chikashi Watase
    Ayumi Ogawa
    Shohei Shikata
    Hiromi Hashiguchi
    Yukiko Yoshii
    Hirokazu Sugino
    Kenjiro Jimbo
    Akiko Maeshima
    Eriko Iwamoto
    Shin Takayama
    Akihiko Suto
    Breast Cancer, 2023, 30 : 1054 - 1064
12345